Trails Edge Capital Partners, LP
CIK 2077247
13F filing for Q2 2026・No. 3,399
- Holdings
- US$629.91M
- Quarter change
- +US$193.38M
- Entries
- 35
- Net bought (estimate)
- +US$150.29M
The quarter change is the holdings' value against the quarter before, price moves included — not what was bought or sold; each institution's page estimates that.
Net bought (estimate)
Each stock's change in shares at the quarter-end price, added up: a new position counts as bought, one sold out as sold, shares held long only. Splits are compared split-adjusted; corporate actions under a new CUSIP are not estimated. An estimate from the filings, not actual trades.
- New 13
- Sold out 4
- Cut 7
- Added 10
- Corporate actions 0
- Unchanged 5
Largest holdings
35 stocks worth US$629.91M, options and bonds left out.
| Stock | This quarter | Shares | Value | Weight |
|---|---|---|---|---|
| LB PHARMACEUTICALS INCCOM SHS | Added | 1,523,022 | US$49.43M | 7.85% |
| NRIXNURIX THERAPEUTICS INCCOM | Cut | 1,573,220 | US$38.17M | 6.06% |
| IMCRIMMUNOCORE HLDGS PLCADS | Added | 1,063,234 | US$33.76M | 5.36% |
| FIRST TRACKS BIOTHERAPEUTICSORD SHS | New | 1,514,000 | US$30.46M | 4.84% |
| 4D MOLECULAR THERAPEUTICS INCOM | Added | 2,227,917 | US$29.63M | 4.70% |
| BMRNBIOMARIN PHARMACEUTICAL INCCOM | New | 512,000 | US$29.3M | 4.65% |
| DESIGN THERAPEUTICS INCCOM | Added | 2,001,282 | US$28.96M | 4.60% |
| XENEXENON PHARMACEUTICALS INCCOM | Unchanged | 440,000 | US$26.56M | 4.22% |
| MIRUM PHARMACEUTICALS INCCOM | Cut | 223,312 | US$26.14M | 4.15% |
| INSMINSMED INCCOM PAR $.01 | New | 230,331 | US$24.56M | 3.90% |
Sign in (free) to see its 35 largest holdings and its trades. Sign in
Filings
The quarter's original 13F filings (SEC).
- 13F-HRFiled August 14, 2026SEC ↗
13F covers long positions in US-listed securities only; the data is SEC's, filed within 45 days of the quarter's end.